http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Improving the therapeutic ratio in head and neck cancer
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic. The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance. This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.
Front Cover; Improving the Therapeutic Ratio in Head and Neck Cancer; Copyright; Aims and Scope for Series ""Cancer Sensitizing Agents for Chemotherapy; About the Series Editor; About the Editor; Aims and Scope for ""Improving the Therapeutic Ratio in Head and Neck Cancer; Preface; Contents; Contributors; Chapter 1: Overview of head and neck cancer management; Introduction; Anatomy; Clinical evaluation; Oropharynx; Epidemiology; Pathology; Anatomy and staging; General treatment approach; Initial surgery; Initial radiation-based therapy; Key clinical research themes; Nasopharynx; Epidemiology
PathologyAnatomy and staging; General treatment approach; Key clinical research themes; Oral cavity; Epidemiology and pathology; Anatomy and staging; General treatment approach; Key clinical research themes; Larynx and hypopharynx; Epidemiology and staging; General treatment approach; Key clinical research themes; Salivary gland tumors; Epidemiology and pathology; Anatomy and staging; General treatment approach and key clinical research themes; Recurrent and metastatic squamous cell carcinoma of the head and neck; Conclusion; References
Chapter 2: The role of molecularly targeted therapies and immunotherapy in head and neck cancerCurrent therapies for recurrent/metastatic disease; Early work with cytotoxic agents; Emergence of targeted therapy against the epidermal growth factor receptor (EGFR); Cetuximab plus chemotherapy in the first line metastatic setting; Panitumumab as an alternative targeted agent for HNSCC; Practical approach to first line systemic treatment; Dawn of an immunotherapy trend; Pembrolizumab; Nivolumab; Durvalumab; Ongoing trials and future directions; Future directions; Acknowledgments; References
Chapter 3: Combining radiation and chemotherapy to improve the therapeutic ratioBasic principles of radiobiology; Basic principles of radiation-induced cell death; Basic principles of radiotherapy in head and neck cancer management; Basic principles of toxicities of head and neck cancer management; Widening the therapeutic window; Radiotherapy dose/volume reduction in the absence of a surgical component or induction chemotherapy; Radiotherapy dose/volume reduction following induction chemotherapy; Systemic therapy toxicity studies without radiotherapy or surgical components
Radiotherapy dose/volume reductions with a surgical componentRadiotherapy protectors; Proton therapy; Conclusion; Acknowledgments; References; Chapter 4: Targeting TP53 to augment therapeutic response in head and neck cancer; Introduction; Current treatment for head and neck squamous cell carcinoma (HNSCC); Mutations in TP53 are common deleterious genetic alterations in HNSCC; Tumor suppressive functions of TP53; TP53 mutations as a prognostic and predictive biomarker for poor outcomes in HNSCC; TP53 gene transfer therapy for HNSCC
Restoration of wild-type p53 confirmation and function in HNSCC as a novel therapeutic approach
Includes bibliographical references and index.
San Diego : Elsevier Science & Technology, ©2019
Cancer sensitizing agents for chemotherapy ; v. 6